Related Experiment Video
Updated: Aug 2, 2026
08:30
Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
Published on: March 12, 2016
Triamcinolone acetonide-induced ocular hypertension
Jost B Jonas1, Gangolf Sauder, Wido M Budde
1Department of Ophthalmology, Faculty of Clinical Medicine Mannheim, Ruprecht-Karls-University of Heidelberg, Heidelberg, Germany. Jost.Jonas@augen.ma.uni-heidelberg.de
Summary
Markedly increased intraocular pressure (IOP) from intravitreal triamcinolone acetonide (TA) in a young patient resolved within 3 months without surgery. This case suggests that prolonged IOP elevation from TA may not always require surgical intervention.
Area of Science:
- Ophthalmology
- Glaucoma Research
- Uveitis Management
Background:
- Intravitreal triamcinolone acetonide (TA) is used for therapy-resistant uveitis.
- Elevated intraocular pressure (IOP) is a known side effect of TA injections.
Observation:
- A 33-year-old patient developed marked IOP elevation (>40 mmHg, peak 55 mmHg) lasting over 3 months after an intravitreal TA injection.
- Maximal antiglaucomatous medical therapy was insufficient to control the IOP.
- No glaucomatous changes were detected via imaging or perimetry, though retinal nerve fiber layer analysis suggested minor nasal loss.
Findings:
- The patient's IOP normalized within approximately 3 months without surgical intervention.
- Despite significant IOP spikes, no definitive glaucomatous damage was observed.
Implications:
- Young patients with significant TA-induced IOP elevation may not require glaucoma surgery if IOP normalizes within 3 months.
- Careful monitoring is crucial for patients receiving intravitreal corticosteroids.
- This case highlights the potential for non-surgical resolution of TA-induced ocular hypertension.
Related Concept Videos
01:25Glaucoma: Overview
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
01:23Ophthalmic Drug Delivery Systems
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...